China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings (CPHI) has reported Finished Goods for 8 consecutive years, with $1.3 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Finished Goods rose 6.83% year-over-year to $1.3 million; the trailing twelve-month figure through Sep 2024 stood at $1.3 million (up 6.83% YoY), and the FY2023 full-year result was $1.5 million, up 166.73% from the prior year.
• Finished Goods slipped to $1.3 million in Q3 2024 per CPHI's latest filing, from $1.5 million in the prior quarter.
• Across five years, Finished Goods topped out at $1.7 million in Q1 2024 and bottomed at $551000.0 in Q4 2021.
• Historically, Finished Goods has averaged $1.2 million across 5 years, with a median of $1.3 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Finished Goods tumbled 46.0% in 2021, then jumped 166.73% in 2023.
• Over 5 years, Finished Goods stood at $960375.0 in 2020, then plunged by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then declined by 11.91% to $1.3 million in 2024.
• According to Business Quant data, Finished Goods over the past three periods registered $1.3 million, $1.5 million, and $1.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.